<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 18 Mar 2021 19:17:21 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>再失利！默克 TGF-β/PD-L1治疗胆道癌 II 期研究失败</title><link>https://mp.weixin.qq.com/s/249ilMpuGc0A_p96SdnJNg</link><description></description><content:encoded><![CDATA[再失利！默克 TGF-β/PD-L1治疗胆道癌 II 期研究失败]]></content:encoded><pubDate>Thu, 18 Mar 2021 18:22:20 +0800</pubDate></item><item><title>Tecentriq vs Keytruda：三阴乳腺癌竞争白热化，一图尽览核心临床布局</title><link>https://mp.weixin.qq.com/s/k5p9lUjMj94Ee2tHW-VPxQ</link><description></description><content:encoded><![CDATA[Tecentriq vs Keytruda：三阴乳腺癌竞争白热化，一图尽览核心临床布局]]></content:encoded><pubDate>Thu, 18 Mar 2021 18:22:20 +0800</pubDate></item><item><title>普利制药地氯雷他定2个新剂型通过一致性评价</title><link>https://mp.weixin.qq.com/s/81qf9CETwy2kRrvnaXS7Mg</link><description></description><content:encoded><![CDATA[普利制药地氯雷他定2个新剂型通过一致性评价]]></content:encoded><pubDate>Thu, 18 Mar 2021 18:22:20 +0800</pubDate></item><item><title>奥赛康与药明康德达成合作，共同开发 NSCLC 1类新药</title><link>https://mp.weixin.qq.com/s/d0KAQ1lA6E7mMT4rIB212Q</link><description></description><content:encoded><![CDATA[奥赛康与药明康德达成合作，共同开发 NSCLC 1类新药]]></content:encoded><pubDate>Thu, 18 Mar 2021 18:22:20 +0800</pubDate></item><item><title>首个口服小分子GLP-1激动剂获批临床，I 期研究降糖、减重强劲</title><link>https://mp.weixin.qq.com/s/Gx_kYpnjbdeP5h6AjJdoHA</link><description></description><content:encoded><![CDATA[首个口服小分子GLP-1激动剂获批临床，I 期研究降糖、减重强劲]]></content:encoded><pubDate>Wed, 17 Mar 2021 18:16:08 +0800</pubDate></item><item><title>厄瓜多尔对默沙东抗HIV药物拉替拉韦宣布专利实施强制许可</title><link>https://mp.weixin.qq.com/s/xDEDGoCrEzE29oAId4uOdQ</link><description></description><content:encoded><![CDATA[厄瓜多尔对默沙东抗HIV药物拉替拉韦宣布专利实施强制许可]]></content:encoded><pubDate>Wed, 17 Mar 2021 18:16:08 +0800</pubDate></item><item><title>百济神州CD3/CD19双抗新适应症上市申请拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/rIZZYAaL_9XNxFbkRlv_VA</link><description></description><content:encoded><![CDATA[百济神州CD3/CD19双抗新适应症上市申请拟纳入优先审评]]></content:encoded><pubDate>Wed, 17 Mar 2021 18:16:08 +0800</pubDate></item><item><title>CDE拟突破性疗法认定，恒瑞CDK4/6 抑制剂、君实抗PD-1</title><link>https://mp.weixin.qq.com/s/OIBegszzcaxjWilPDpCEIQ</link><description></description><content:encoded><![CDATA[CDE拟突破性疗法认定，恒瑞CDK4/6 抑制剂、君实抗PD-1]]></content:encoded><pubDate>Wed, 17 Mar 2021 18:16:08 +0800</pubDate></item><item><title>贝达EGFR/c-Met双抗获批临床</title><link>https://mp.weixin.qq.com/s/6kqaesToE1woqkHAgOWaBA</link><description></description><content:encoded><![CDATA[贝达EGFR/c-Met双抗获批临床]]></content:encoded><pubDate>Wed, 17 Mar 2021 18:16:08 +0800</pubDate></item><item><title>司美格鲁肽治疗NASH获CDE拟突破性疗法认定</title><link>https://mp.weixin.qq.com/s/izfAtsY6SLDaF_82IGsLaQ</link><description></description><content:encoded><![CDATA[司美格鲁肽治疗NASH获CDE拟突破性疗法认定]]></content:encoded><pubDate>Tue, 16 Mar 2021 17:16:43 +0800</pubDate></item><item><title>辉瑞JAK1抑制剂在华上市申请拟纳入优先审评，治疗特应性皮炎</title><link>https://mp.weixin.qq.com/s/SFvPTCvE19QUQtcEmgiFDw</link><description></description><content:encoded><![CDATA[辉瑞JAK1抑制剂在华上市申请拟纳入优先审评，治疗特应性皮炎]]></content:encoded><pubDate>Tue, 16 Mar 2021 17:16:43 +0800</pubDate></item><item><title>首个宫颈癌2线疗法 III 期研究成功！</title><link>https://mp.weixin.qq.com/s/boYZ1VE-yvLtcRE4d9l5Xw</link><description></description><content:encoded><![CDATA[首个宫颈癌2线疗法 III 期研究成功！]]></content:encoded><pubDate>Tue, 16 Mar 2021 17:16:43 +0800</pubDate></item><item><title>首家！重庆药友递交抗精神病药上市申请</title><link>https://mp.weixin.qq.com/s/y6UgkUWryw8GDi7tbQBXcw</link><description></description><content:encoded><![CDATA[首家！重庆药友递交抗精神病药上市申请]]></content:encoded><pubDate>Tue, 16 Mar 2021 17:16:43 +0800</pubDate></item><item><title>AD/PD 2021：Biogen公布阿尔茨海默症新药aducanumab III期研究数据</title><link>https://mp.weixin.qq.com/s/hvq2LJVLY_zNpmdcyOM0VA</link><description></description><content:encoded><![CDATA[AD/PD 2021：Biogen公布阿尔茨海默症新药aducanumab III期研究数据]]></content:encoded><pubDate>Mon, 15 Mar 2021 18:39:15 +0800</pubDate></item><item><title>首仿！东阳光「恩他卡朋片」即将获批上市</title><link>https://mp.weixin.qq.com/s/X8uQ11-eWCj91chU5WvBXw</link><description></description><content:encoded><![CDATA[首仿！东阳光「恩他卡朋片」即将获批上市]]></content:encoded><pubDate>Mon, 15 Mar 2021 18:39:15 +0800</pubDate></item><item><title>冠脉扩张球囊类医用耗材集采来了，京津冀“3+N”联盟形成</title><link>https://mp.weixin.qq.com/s/4Mf66CxLrqa8aLY721ufKw</link><description></description><content:encoded><![CDATA[冠脉扩张球囊类医用耗材集采来了，京津冀“3+N”联盟形成]]></content:encoded><pubDate>Mon, 15 Mar 2021 18:39:15 +0800</pubDate></item><item><title>恩华药业1类抗抑郁新药获批临床</title><link>https://mp.weixin.qq.com/s/8KaG2SZKNs10lPn4omi2Bg</link><description></description><content:encoded><![CDATA[恩华药业1类抗抑郁新药获批临床]]></content:encoded><pubDate>Mon, 15 Mar 2021 18:39:15 +0800</pubDate></item><item><title>上海凯茂生物「注射用人干扰素γ」上市申请拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/rC1ixpRTpMVyDwouYgqfKg</link><description></description><content:encoded><![CDATA[上海凯茂生物「注射用人干扰素γ」上市申请拟纳入优先审评]]></content:encoded><pubDate>Mon, 15 Mar 2021 18:39:15 +0800</pubDate></item><item><title>首仿！海思科「阿伐那非片」即将获批上市</title><link>https://mp.weixin.qq.com/s/cWc_eZRqUEOxET_ZmZtv-Q</link><description></description><content:encoded><![CDATA[首仿！海思科「阿伐那非片」即将获批上市]]></content:encoded><pubDate>Sat, 13 Mar 2021 13:13:36 +0800</pubDate></item><item><title>首仿！奥赛康「艾曲泊帕乙醇胺片」即将获批上市</title><link>https://mp.weixin.qq.com/s/8GmeSeqia6mH20YR_QmXsw</link><description></description><content:encoded><![CDATA[首仿！奥赛康「艾曲泊帕乙醇胺片」即将获批上市]]></content:encoded><pubDate>Sat, 13 Mar 2021 13:13:36 +0800</pubDate></item></channel></rss>